Defined Distribution Network for BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib)

December 2018

This notice provides information for 340B covered entities regarding how to acquire the following BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib) NDC-11s at the 340B price:

<table>
<thead>
<tr>
<th>NDC</th>
<th>Product Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>70255-0025-01</td>
<td>BRAFTOVI (encorafenib) 75 mg Capsules</td>
</tr>
<tr>
<td>70255-0020-01</td>
<td>BRAFTOVI (encorafenib) 50 mg Capsules</td>
</tr>
<tr>
<td>70255-0010-02</td>
<td>MEKTOVI (binimetinib) 15 mg Tablets</td>
</tr>
</tbody>
</table>

BRAFTOVI and MEKTOVI are orphan oral oncology drugs used in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.

To support high quality care for patients taking BRAFTOVI and MEKTOVI, and to ensure optimal therapeutic adherence, Array BioPharma Inc. ("Array") has developed a limited distribution plan—a defined network of specialty pharmacies and specialty distributors—designed to achieve these goals. All customers, 340B and otherwise, are subject to this plan equally.

Array’s defined distribution network for BRAFTOVI and MEKTOVI currently consists of the following five specialty pharmacies:

- Avella of Deer Valley, Inc.;
- Biologics, Inc.;
- Diplomat Pharmacy, Inc.;
- Onco360 Oncology Pharmacy (OncoMed Specialty LLC); and
- US Bioservices Corporation.

These specialty pharmacies, which have deep oncology expertise, provide ongoing supportive care to patients who are prescribed BRAINTOVI and MEKTOVI, offer programs to support patients’ access to prescribed medications, have distribution capabilities that comply with applicable law, can report adverse events and other data to Array, and possess URAC accreditation.1

In addition to the specialty pharmacies in Array’s defined distribution network, a select number of (a) Oncology Group Practices with on-site dispensing pharmacies that are members of Oncology Group Purchasing Organizations, and (b) healthcare facilities that maintain in-house pharmacies that are equipped to meet the specific needs of oncology patients (including, for example, by maintaining an on-

---

1 URAC is a nationally-recognized accreditor of specialty pharmacies.
site prescribing oncologist and staff to monitor patients on cancer medications) are eligible to purchase BRAFTOVI and MEKTOVI from Array’s network of authorized specialty distributors.

Array’s specialty distributor partners currently include the following five entities focused on providing specialty pharmacy distribution:

- McKesson Plasma & Biologics LLC;
- McKesson Specialty Health;
- Oncology Supply;
- ASD Healthcare; and
- Cardinal Specialty.

Array takes seriously both its obligations to protect patient safety and to comply with the 340B Program statute and has designed its limited distribution plan accordingly and in a manner that ensures all purchasers—both covered entities and non-covered entities—are treated equally. Array’s defined distribution network may change from time to time. If a covered entity has any questions regarding how it may access BRAFTOVI or MEKTOVI at the 340B price for its eligible patients, please contact Array at tradeanddistribution@arraybiopharma.com or 1-866-ARRAYCS (277-2927).